TSO3 first quarter revenue decreases to $136,628

TSO₃ Inc. ("TSO₃") (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, posted revenues of $136,628 for the first quarter of 2011 ending March 31, for the sale of supplies, accessories and service contracts for the first generation product. This compares to $144,228 in the first quarter of 2010, for the same type of products. The Company recorded a net loss of $1,880,010 for the first quarter of 2011, or $0.03 per share, compared to a net loss of $2,056,556 or $0.04 for the same period in 2010.

"In the first quarter, we concluded several months of crucial work - the verification and validation as well as the reliability testing for the new sterilizer. This was mandatory to ensure that we produce quality sterilizers that perform consistently to customer expectations", said R.M. (Ric) Rumble President and CEO of TSO₃.

"As planned and announced in our last investor conference call, we recently conducted a second meeting with the US regulatory agency concerning the new sterilizer.  We are pleased with the exchange of information and the feedback that we received. The meeting allowed us to review our filing strategy and to define a filing date estimate which is now targeted as late June 2011", said Mr. Rumble. "We remain confident in our ability to obtain the required clearance for the US market".